The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Executes the first project for developing and manufacturing a novel anticancer mAb
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Subscribe To Our Newsletter & Stay Updated
